Amyloid blood biomarker of Alzheimer’s disease using single-molecule detection
| Reference number | |
| Coordinator | AmyloiDia Sweden AB |
| Funding from Vinnova | SEK 300 000 |
| Project duration | May 2021 - December 2021 |
| Status | Completed |
| Venture | Innovative Startups |
| Call | Innovative Startups step 1 spring 2021 |
Important results from the project
The purpose of this project is to translate to healthcare an innovative method with the ultimate, single-molecule sensitivity to enable fast and cost-effective measurement of the concentration and size of structured protein aggregates, so-called amyloids, in the blood. Buildup of structured protein aggregates is a hallmark of a number of diseases, commonly called amyloid diseases. The ability to detect amyloid formation at the inception of this process is invaluable for an early and reliable diagnosis of amyloid diseases, such as Alzheimer´s disease.
Expected long term effects
Funding from this project was used to take the first steps in building a prototype of a portable, plug-and-play instrument for massively parallel, time-resolved fluorescence intensity fluctuation measurements.
Approach and implementation
We have finalized the so-called "paper design" prototype development phase, have specified components needed to build a physical prototype, ordered relevant components and the production of custom-made components. The assembly phase will be initiated as soon as we receive the ordered parts. We have also identified a prospective partner for the development of our device in accordance with In Vitro Diagnostic Regulation (IVDR) and prepare technical documentation for CE marking.